Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RANEE MEHRA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1760411326
CMS profile
170140
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$273.81

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $273.81 10

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RANEE MEHRA

NPI 1760411326 · CMS profile ID 170140

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760411326?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760411326?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760411326?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RANEE MEHRA, NPI 1760411326, CMS profile ID 170140, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1760411326?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $273.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Caris MPI, Inc. $17.3311/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234283090 CMS
Merck Sharp & Dohme LLC $24.6410/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238267382 CMS
SERVIER PHARMACEUTICALS LLC $16.1210/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229109143 CMS
Daiichi Sankyo Inc. $26.4610/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197032115 CMS
Syndax Pharmaceuticals, Inc. $24.7110/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238993222 CMS
Janssen Biotech, Inc. $44.1809/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174698775 CMS
Daiichi Sankyo Inc. $29.9408/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197017353 CMS
Daiichi Sankyo Inc. $25.1406/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197081769 CMS
Merck Sharp & Dohme LLC $31.7202/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238043145 CMS
JAZZ PHARMACEUTICALS INC. $33.5702/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234318892 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,242.50 5
PY2022 $4,211.09 5
PY2023 $917.82 20
PY2024 $2,617.99 14
PY2025 $273.81 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,124,333.75 93
PY2024 Principal investigator $813,892.28 61
PY2023 Principal investigator $633,471.41 125
PY2022 Principal investigator $830,697.81 139
PY2021 Recipient $330.00 1
PY2021 Principal investigator $979,164.73 91
PY2020 Principal investigator $622,730.93 67
PY2019 Principal investigator $214,554.45 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

139 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,967.37 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 914601467
Principal investigator 1 Merck Sharp & Dohme LLC $147,684.32 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE
Phase II Study of pembrolizumab and bavituximab for recurrent,metastatic SCCN No dispute reported 06/30/2026 940388267
Principal investigator 1 Merck Sharp & Dohme LLC $7,761.47 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 940391171
Principal investigator 1 Merck Sharp & Dohme LLC $28,472.40 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 940391207
Principal investigator 1 Merck Sharp & Dohme LLC $2,906.88 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 940391343
Principal investigator 1 Merck Sharp & Dohme LLC $7,016.42 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy for Advanced Non Small Cell Lung Cancer KEYNOTE-495 KeyImPaCT No dispute reported 06/30/2026 940406949
Principal investigator 1 Merck Sharp & Dohme LLC $1,297.48 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy for Advanced Non Small Cell Lung Cancer KEYNOTE-495 KeyImPaCT No dispute reported 06/30/2026 940406951
Principal investigator 1 Merck Sharp & Dohme LLC $12,681.56 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 940409553
Principal investigator 1 Merck Sharp & Dohme LLC $95,439.61 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 940409555
Principal investigator 1 Merck Sharp & Dohme LLC $4,125.29 12/31/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 940409701
Principal investigator 1 Merck Sharp & Dohme LLC $136.76 12/31/2022 Non-covered Recipient Entity
University of Maryland
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 964705917
Principal investigator 1 Merck Sharp & Dohme LLC $46,783.74 12/07/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 940409551
Principal investigator 1 Merck Sharp & Dohme LLC $31,584.00 12/05/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 940391169
Principal investigator 1 Incyte Corporation $650.00 12/02/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233899
Principal investigator 1 Incyte Corporation $1,724.00 12/02/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233901
Principal investigator 1 Merck Sharp & Dohme LLC $131,267.92 11/08/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND MARLENE AND STEWART GREENEBAUM CANCER CENTER
A Phase II, Open-Label, Multi-Center Trial of PDS0101 ImmunoMAPK-RDOTAP,HPV-16 E6 & E7 peptides and Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Cancer and High-risk Human Papillomavirus-16 HPV16 Infection after Failure with Platinum-Based Chemotherapy No dispute reported 06/30/2026 940418703
Principal investigator 1 Incyte Corporation $2,535.00 11/04/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233897
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,595.63 10/26/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer No dispute reported 06/30/2026 914597389
Principal investigator 1 Merck Sharp & Dohme LLC $90,712.00 10/15/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND MEDICAL GROUP
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 940392137
Principal investigator 1 AstraZeneca UK Limited $4,432.64 10/14/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND, BALTIMORE
An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE No dispute reported 06/30/2026 914601933
Principal investigator 1 Novocure Inc. $812.50 09/22/2022 Non-covered Recipient Entity
University of Maryland, Baltimore
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 950633259
Principal investigator 1 MACROGENICS, INC. $2,604.74 09/13/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 2 OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 936959417
Principal investigator 1 MACROGENICS, INC. $1,108.40 09/13/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 2 OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 936959421
Principal investigator 1 MACROGENICS, INC. $1,828.86 09/13/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 2 OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 936959428
Principal investigator 1 Incyte Corporation $66.80 09/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233851
Principal investigator 1 Incyte Corporation $50.10 09/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233853
Principal investigator 1 Incyte Corporation $50.10 09/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233891
Principal investigator 1 GlaxoSmithKline, LLC. $3,900.00 08/17/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940311
Principal investigator 1 GlaxoSmithKline, LLC. $3,250.00 08/17/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940315
Principal investigator 1 GlaxoSmithKline, LLC. $3,024.84 08/17/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940321
Principal investigator 1 GlaxoSmithKline, LLC. $4,705.00 08/17/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940323
Principal investigator 1 GlaxoSmithKline, LLC. $3,055.00 08/17/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940325
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 08/17/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940327
Principal investigator 1 GlaxoSmithKline, LLC. $283.00 08/17/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940333
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.00 08/17/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940337
Principal investigator 1 Blueprint Medicines Corporation $863.00 08/11/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC No dispute reported 06/30/2026 958948743
Principal investigator 1 GlaxoSmithKline, LLC. $1,950.00 07/18/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940313
Principal investigator 1 GlaxoSmithKline, LLC. $862.50 07/18/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940317
Principal investigator 1 GlaxoSmithKline, LLC. $325.00 07/18/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940329
Principal investigator 1 GlaxoSmithKline, LLC. $862.50 07/18/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940331
Principal investigator 1 GlaxoSmithKline, LLC. $2,535.00 07/18/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940341
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.00 07/18/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940347
Principal investigator 1 GlaxoSmithKline, LLC. $2,535.00 07/11/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940335
Principal investigator 1 GlaxoSmithKline, LLC. $390.00 07/11/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940339
Principal investigator 1 GlaxoSmithKline, LLC. $390.00 07/11/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940345
Principal investigator 1 GlaxoSmithKline, LLC. $862.50 07/11/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940349
Principal investigator 1 GlaxoSmithKline, LLC. $862.50 07/11/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940351
Principal investigator 1 Incyte Corporation $30.92 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233855
Principal investigator 1 Incyte Corporation $35.16 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233857
Principal investigator 1 Incyte Corporation $1.56 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233859
Principal investigator 1 Incyte Corporation $30.63 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233861
Principal investigator 1 Incyte Corporation $12.24 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233863
Principal investigator 1 Incyte Corporation $15.64 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233865
Principal investigator 1 Incyte Corporation $24.08 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233867
Principal investigator 1 Incyte Corporation $48.75 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233869
Principal investigator 1 Incyte Corporation $12.30 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233871
Principal investigator 1 Incyte Corporation $10.20 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233873
Principal investigator 1 Incyte Corporation $2.97 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233875
Principal investigator 1 Incyte Corporation $128.64 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233877
Principal investigator 1 Incyte Corporation $75.06 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233879
Principal investigator 1 Incyte Corporation $6.39 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233881
Principal investigator 1 Incyte Corporation $2.84 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233883
Principal investigator 1 Incyte Corporation $20.26 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233885
Principal investigator 1 Incyte Corporation $1.08 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233887
Principal investigator 1 Incyte Corporation $65.89 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233889
Principal investigator 1 Incyte Corporation $30.63 07/11/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233893
Principal investigator 1 Incyte Corporation $2,535.00 07/06/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233843
Principal investigator 1 MACROGENICS, INC. $1,466.40 07/01/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 2 OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 936958263
Principal investigator 1 MACROGENICS, INC. $624.00 07/01/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 2 OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 936958269
Principal investigator 1 MACROGENICS, INC. $1,029.60 07/01/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 2 OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 936958275
Principal investigator 1 Seagen Inc. $7,967.50 06/29/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 917851357
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 06/27/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940319
Principal investigator 1 GlaxoSmithKline, LLC. $24,064.88 06/15/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 943940343
Principal investigator 1 Merck Sharp & Dohme LLC $9,370.00 06/15/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy for Advanced Non Small Cell Lung Cancer KEYNOTE-495 KeyImPaCT No dispute reported 06/30/2026 940406911
Principal investigator 1 Novocure Inc. $1,592.50 06/10/2022 Non-covered Recipient Entity
University of Maryland, Baltimore
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 950633249
Principal investigator 1 Seagen Inc. $61.44 06/02/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 917851345
Principal investigator 1 Incyte Corporation $62.55 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233755
Principal investigator 1 Incyte Corporation $51.05 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233757
Principal investigator 1 Incyte Corporation $107.20 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233759
Principal investigator 1 Incyte Corporation $194.00 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233761
Principal investigator 1 Incyte Corporation $3.55 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233763
Principal investigator 1 Incyte Corporation $0.60 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233765
Principal investigator 1 Incyte Corporation $6.80 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233767
Principal investigator 1 Incyte Corporation $120.40 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233769
Principal investigator 1 Incyte Corporation $1.65 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233771
Principal investigator 1 Incyte Corporation $35.08 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233773
Principal investigator 1 Incyte Corporation $2.72 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233775
Principal investigator 1 Incyte Corporation $14.70 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233777
Principal investigator 1 Incyte Corporation $19.38 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233779
Principal investigator 1 Incyte Corporation $6.24 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233781
Principal investigator 1 Incyte Corporation $32.70 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233783
Principal investigator 1 Incyte Corporation $66.00 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233785
Principal investigator 1 Incyte Corporation $65.40 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233787
Principal investigator 1 Incyte Corporation $49.95 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233789
Principal investigator 1 Incyte Corporation $98.48 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233791
Principal investigator 1 Incyte Corporation $7.13 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233793
Principal investigator 1 Incyte Corporation $20.26 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233795
Principal investigator 1 Incyte Corporation $0.24 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233797
Principal investigator 1 Incyte Corporation $24.08 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233799
Principal investigator 1 Incyte Corporation $1.56 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233801
Principal investigator 1 Incyte Corporation $64.00 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233803
Principal investigator 1 Incyte Corporation $25.60 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233805
Principal investigator 1 Incyte Corporation $5.68 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233807
Principal investigator 1 Incyte Corporation $62.29 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233809
Principal investigator 1 Incyte Corporation $8.35 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233811
Principal investigator 1 Incyte Corporation $24.72 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233813
Principal investigator 1 Incyte Corporation $38.40 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233815
Principal investigator 1 Incyte Corporation $34.25 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233817
Principal investigator 1 Incyte Corporation $15.64 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233819
Principal investigator 1 Incyte Corporation $0.68 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233821
Principal investigator 1 Incyte Corporation $51.05 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233823
Principal investigator 1 Incyte Corporation $62.55 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233825
Principal investigator 1 Incyte Corporation $107.20 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233827
Principal investigator 1 Incyte Corporation $98.48 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233829
Principal investigator 1 Incyte Corporation $32.70 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233831
Principal investigator 1 Incyte Corporation $32.70 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233833
Principal investigator 1 Incyte Corporation $8.35 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233835
Principal investigator 1 Incyte Corporation $8.35 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233839
Principal investigator 1 Incyte Corporation $8.35 05/09/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233841
Principal investigator 1 Novocure Inc. $726.00 05/05/2022 Non-covered Recipient Entity
University of Maryland, Baltimore
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 950633247
Principal investigator 1 MACROGENICS, INC. $11,271.07 05/04/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 2 OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 936957445
Principal investigator 1 MACROGENICS, INC. $4,796.20 05/04/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 2 OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 936957451
Principal investigator 1 MACROGENICS, INC. $7,913.73 05/04/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 2 OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 936957457
Principal investigator 1 PFIZER INC. $3,835.00 04/07/2022 Non-covered Recipient Entity
University of Maryland Baltimore
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF SASANLIMAB COMBINED WITH ANTICANCER THERAPIES TARGETING MULTIPLE MOLECULAR MECHANISMS IN PARTICIPANTS WITH NONSMALL CELL LUNG CANCER NSCLC No dispute reported 06/30/2026 949808783
Principal investigator 1 Incyte Corporation $1,300.00 03/31/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233721
Principal investigator 1 Incyte Corporation $650.00 03/31/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233723
Principal investigator 1 Incyte Corporation $7,000.00 03/31/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233725
Principal investigator 1 Incyte Corporation $4,705.00 03/31/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233727
Principal investigator 1 Incyte Corporation $3,900.00 03/31/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233729
Principal investigator 1 Incyte Corporation $3,250.00 03/31/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233731
Principal investigator 1 Incyte Corporation $283.00 03/31/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233733
Principal investigator 1 Incyte Corporation $3,055.00 03/31/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233735
Principal investigator 1 Incyte Corporation $1,950.00 03/31/2022 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905233737
Principal investigator 1 AstraZeneca UK Limited $9,541.46 03/22/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE No dispute reported 06/30/2026 914603609
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,605.00 03/15/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A Phase 1b 2a Multi Center Open Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 INO 3112 and Durvalumab MEDI4736 in Patients with Recurrent Metastatic Human Papilloma Virus Associated Head and Neck Squamous Cancer No dispute reported 06/30/2026 914602349
Principal investigator 1 Novocure Inc. $812.50 03/11/2022 Non-covered Recipient Entity
University of Maryland, Baltimore
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 950633243
Principal investigator 1 PFIZER INC. $11,443.00 03/02/2022 Non-covered Recipient Entity
University of Maryland Baltimore
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06939999 PRMT5 INHIBITOR IN PARTICIPANTS WITH ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA ESOPHAGEAL CANCER ENDOMETRIAL CANCER CERVICAL CANCER AND BLADDER CANCER No dispute reported 06/30/2026 949808711
Principal investigator 1 Blueprint Medicines Corporation $7,558.00 02/03/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC No dispute reported 06/30/2026 958948745
Principal investigator 1 Seagen Inc. $2,103.40 02/02/2022 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 917851351